|
مقاله
|
Abstract
|
|
|
Title:
|
The Effect of Intravitreal Recombinant Tissue Plasminogen Activator Injection on Diabetic Tractional Fibrovascular Membranes: Proposed Criteria using Optical Coherence Tomography
|
Author(s):
|
Khalil Ghasemi Falavarjani, Pasha Anvari, Mohamadhassan Dehghan, Saber Molaei, Pegah Kazemi
|
Presentation Type:
|
Oral
|
Subject:
|
Posterior Segment
|
Others:
|
|
Presenting Author:
|
|
Name:
|
Pasha Anvari
|
Affiliation :(optional)
|
Eye Research Center and Eye Department, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
|
E mail:
|
anvari.pasha@gmail.com
|
Phone:
|
88010558
|
Mobile:
|
09122490767
|
|
|
Purpose:
|
o evaluate the effect of intravitreal recombinant tissue plasminogen activator (rTPA) on diabetic tractional fibrovascular membranes (FVM) using the proposed optical coherence tomography (OCT) based measurement criteria.
|
Methods:
|
This prospective, interventional case series enrolled eyes that were candidates for vitrectomy. OCT images were obtained to study attached–detached retinal borders at baseline and on- week post-intravitreal rTPA injection using the follow-up scan protocols. Two independent graders assessed retinal detachment (RD) height, FVM height, FVM thickness, retinal thickness at the site of membrane attachment and release of retina-membrane touch point.
|
Results:
|
Nine eyes from nine individuals were included. Assessment of RD height, FVM height, FVM thickness and retinal thickness at touch point were feasible in 8/9 (88%), 7/9 (77%), 8/9 (88%) and 5/9 (55%) of eyes, respectively. There was an excellent agreement between the two graders in all of measurements (all ICC> 0.93). Release of retina-membrane touch point was not observed in any eyes. No statistically significant change was found in any of the measured parameters.
|
Conclusion:
|
Our proposed OCT-based measurement system in assessing diabetic FVM was reliable and feasible. We did not find any significant change in the status of diabetic FVM, one-week after intravitreal rTPA injection, using OCT-based measurements.
|
Attachment:
|
|
|
|